PathFree

Advisory Board
& Investment Application

PathFree Technologies is transforming emergency heart care with our DataSyteAiCLS system. This technology assists medical professionals in performing CPR and advanced cardiovascular life support procedures with greater accuracy and speed, ultimately saving more lives.

Our AI-driven system provides real-time guidance, rhythm interpretation, and feedback, which reduces errors and improves patient outcomes during critical moments.

We are currently seeking advisory board members who are passionate about advancing healthcare technology and are interested in participating in our angel funding round. Your expertise and experience could be invaluable to our mission.

Responsibilities of Advisors & Investors:*

Provide feedback and guidance to the management team and other advisors (via email, Zoom) on company growth and strategies.*

Facilitate introductions to potential customers or partners.

Benefits to Advisors
& Investors:*

Receive stock options in exchange for dedicating a few hours each month to the company.*

Opportunity to invest $25K+ as an angel before valuation increases. You can also use your IRA/401K.

First Name

Last Name

Phone Number

What is your LinkedIn URL?

How do you think you could contribute to PathFree's advisory board?

Would you strongly consider making a $25,000+ angel investment in PathFree's current funding round in the next 60-90 days? Note that investors can use an IRA/401K to invest.

Are you an accredited investor? The SEC defines accredited investors as individuals with a $200K+ income OR $300k+ income with a spouse or $1M net worth.

The Company shall be entitled to a 50% profits interest in any net profits realized by PathFree Technologies in connection with its inventions and intellectual property for a five (5) year term (the “Term”); and at the conclusion of the Term, Members of the Company holding Convertible Common Units shall have the right and option to either: Receive a 100% return of their Capital Contribution to the Company (a “Redemption”); or Convert their Units into shares of voting common stock in PathFree Technologies on a 1:1 basis (a “Conversion”, i.e., 1 Unit converts into 1 share).

Notwithstanding the foregoing, at their sole option, the Manager of the Company may effect either a Redemption or a Conversion of all of the Company’s outstanding Convertible Common Units in the event PathFree Technologies enters into any merger agreement or adopts a plan in which it or its successors or assigns either (a) is sold to a third-party purchaser; or (b) is to become listed or quoted on an established securities market or exchange (for example, NASDAQ, NYSE) or becomes readily tradable on a secondary market (or the substantial equivalent thereof) (i.e., a “Public Event”).

NOTICE: NOT AN OFFER TO SELL OR A SOLICITATION TO BUY. AVAILABLE TO ACCREDITED INVESTORS AND/OR OTHERWISE QUALIFIED INVESTORS ONLY PER REGULATION D PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND/OR OTHER APPLICABLE U.S. FEDERAL AND STATE EXEMPTIONS FROM REGISTRATION. The material and content presented herein is qualified in its entirety by an offering memorandum (the “Memorandum”) which contains more complete information including risk factors. The material and content herein contains forward-looking statements and hypothetical economic forecasts that may not be realized. By receiving or viewing this material, you acknowledge and agree not to rely upon it in making an investment decision. Please read the Memorandum. This material and content do not constitute or form a part of any offer to sell or solicitation to buy securities nor shall it or any part of it form the basis of any contract or commitment whatsoever. Without limiting the foregoing, this material and content do not constitute an offer or solicitation in any jurisdiction in which such an offer or solicitation is not permitted under applicable law or to any person or entity who is not an “accredited investor” as defined under Rule 501(a) of the U.S. Securities Act of 1933, as amended, and/or who does not possess the necessary qualifications described in the Memorandum and/or applicable exemptions under the U.S. Securities Act of 1933, as amended. Please read the Memorandum.